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Abstract
Background:  WGA (Whole Genome Amplification) in forensic genetics can eliminate the
technical limitations arising from low amounts of genomic DNA (gDNA). However, it has not been
used to date because any amplification bias generated may complicate the interpretation of results.
Our aim in this paper was to assess the applicability of MDA to forensic SNP genotyping by
performing a comparative analysis of genomic and amplified DNA samples. A 26-SNPs TaqMan
panel specifically designed for low copy number (LCN) and/or severely degraded genomic DNA
was typed on 100 genomic as well as amplified DNA samples.
Results: Aliquots containing 1, 0.1 and 0.01 ng each of 100 DNA samples were typed for a 26-
SNPs panel. Similar aliquots of the same DNA samples underwent multiple displacement
amplification (MDA) before being typed for the same panel. Genomic DNA samples showed 0%
PCR failure rate for all three dilutions, whilst the PCR failure rate of the amplified DNA samples
was 0% for the 1 ng and 0.1 ng dilutions and 0.077% for the 0.01 ng dilution. The genotyping results
of both the amplified and genomic DNA samples were also compared with reference genotypes of
the same samples obtained by direct sequencing. The genomic DNA samples showed genotype
concordance rates of 100% for all three dilutions while the concordance rates of the amplified
DNA samples were 100% for the 1 ng and 0.1 ng dilutions and 99.923% for the 0.01 ng dilution.
Moreover, ten artificially-degraded DNA samples, which gave no results when analyzed by current
forensic methods, were also amplified by MDA and genotyped with 100% concordance.
Conclusion:  We investigated the suitability of MDA material for forensic SNP typing.
Comparative analysis of amplified and genomic DNA samples showed that a large number of SNPs
could be accurately typed starting from just 0.01 ng of template. We found that the MDA
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genotyping call and accuracy rates were only slightly lower than those for genomic DNA. Indeed,
when 10 pg of input DNA was used in MDA, we obtained 99.923% concordance, indicating a
genotyping error rate of 1/1299 (7.7 × 10-4). This is quite similar to the genotyping error rate of
STRs used in current forensic analysis. Such efficiency and accuracy of SNP typing of amplified DNA
suggest that MDA can also generate large amounts of genome-equivalent DNA from a minimal
amount of input DNA. These results show for the first time that MDA material is suitable for SNP-
based forensic protocols and in general when samples fail to give interpretable STR results.
Background
Data on human genetic variations are being generated and
used to improve understanding of human origins, indi-
vidual susceptibility to illness, the causes of disease and
the genetic determinants of responses to drugs. The same
kinds of data that are used to analyze genetic differences
among humans for medical purposes can be also used in
courts of law to determine identity. Forensic genetics is the
branch of genetics that, through DNA analysis and com-
parison, helps to resolve legal problems such as paternity
tests, establishing identity in criminal cases where biolog-
ical evidence is found at crime scenes, inheritance matters,
identification of victims of mass disasters, and identifica-
tion of missing persons from human remains [1,2]. In
forensic genetics, DNA samples are analyzed by compar-
ing DNA sequences that are unique to each individual.
Although more than 99.5% of the genome is the same
throughout the human population, variations in DNA
sequence called polymorphisms can be used both to dif-
ferentiate and to correlate individuals. Short Tandem
Repeats (STRs) are the polymorphisms most commonly
used as markers by forensic scientists. STRs consist of
repetitive units of DNA that are 2–6 bp in length. The
number of repeats in STR markers differs markedly among
individuals, which make them effective for human identi-
fication purposes. Currently, different optimized multi-
plex assays are utilized to analyze multiple independent
STR loci located on different chromosomes. The combina-
tion of alleles typed in each locus provides an exclusive
genetic profile with a high power of discrimination for
each individual, i.e. the probability of being able to dis-
criminate between two people chosen at random from a
given population [3].
However, a forensic laboratory often has to deal with
DNA samples that are less than ideal. The technical capac-
ity to analyze samples expected to contain very few cells is
often limited by the quality and quantity of DNA. The
main limitation of existing forensic DNA protocols lies in
the minimum size and/or amount of DNA fragments that
can be typed by a capillary electrophoresis assay (ranging
from 100–400 bases in length and from 500–1250 pg)
[4]. Sometimes forensic samples may contain only small
amounts of genomic DNA (less than 100 pg), referred to
as LCN DNA (low copy number DNA), and/or may also
be degraded into fragments smaller than 100 bp, resulting
in failure of amplification of the STR loci and an incom-
plete DNA profile with lower discriminatory power [5]. To
overcome this problem, several protocols for whole
genome amplification (WGA) have been developed. The
aim of WGA is to amplify a limited DNA sample non-spe-
cifically in order to generate a new sample that is indistin-
guishable from the original but has a higher DNA
concentration. This method was specifically designed to
increase the quantities of DNA in clinically relevant sam-
ples such as single cell analysis, pre-implantation genetic
diagnosis and forensic typing [6]. However, the applica-
tion of WGA methods to forensic casework is demanding
because of technical artefacts that are particularly relevant
when STR markers are analyzed. Such artefacts include
contamination, PCR failure, preferential allele amplifica-
tion, the complete absence of one allele (allele drop-out,
ADO) in heterozygous loci and the non-specific genera-
tion of extra alleles (allele drop-in) [7,8]. Recently, an iso-
thermal WGA method was introduced using
bacteriophage Φ29 DNA polymerase and random hex-
amer primers [9,10]. This method, termed MDA (Multiple
Displacement Amplification), takes advantage of the bac-
teriophage Φ29 DNA polymerase, a proofreading enzyme
with high fidelity and potent strand displacement activi-
ties. MDA is based on the isothermal strand displacement
mechanism and leads to hyperbranching amplification of
both circular and linear DNA templates [10]. Its advan-
tages include limited bias in the amplification of loci
(maximally 6-fold compared to 103- to 106-fold in PCR-
based methods), higher average length of amplification
products (12 kb compared to 100–1000 bp in PCR-based
methods), lower error rate (<10-6 compared to 3 × 10-4 to
10-5 for alternative methods) and higher DNA yield [11].
Recent data have shown that the distance to telomere pre-
dicts failure only in WGA samples while percentage-GC is
positively correlated with PCR failure [12,13]. MDA has
been recognized as the most effective WGA method but its
applicability to forensic casework has not yet been consid-
ered because technical artefacts have not been eliminated
[14,15]. Significantly more alleles are revealed when STRs
are analyzed by application of MDA to LCN samples than
to non-amplified control samples although false allele
generation (allele drop-in) was reported. The cause of
such artifacts are not yet completely explained although itBMC Genomics 2009, 10:159 http://www.biomedcentral.com/1471-2164/10/159
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appears more frequent in STRs analysis [7,16]. Moreover
STR analysis in MDA samples also shows an increased
number and height of stutter peaks together with a high
level of allelic imbalance, affecting the interpretation of
results, especially in cases where two or more individuals
may have contributed to the DNA evidence [16,17]. Stut-
ter peaks result from the PCR process when STR loci are
copied by a DNA polymerase. Because stutter products are
the same size as actual allele PCR products, it can be chal-
lenging to determine whether a small peak is a real allele
from a minor contributor or a stutter product of an adja-
cent allele especially when the height of the stutter is
higher than that normally expected [18].
Moreover, comparative analysis of genomic and MDA
samples starting from 6 ng of DNA reported only a 90–
95% concordance rate for STRs [19,20]. The amount of
template gDNA required for the MDA reaction is also a
critical determinant of genotyping performance because it
is generally unacceptable for forensic purposes. Thus,
since current forensic profiling is based on STRs and the
concordance rate with LCN DNA has not proved accepta-
ble for forensic profiling, MDA is not regarded as valuable
for typical forensic casework. However, better concord-
ance rates were observed when MDA was applied to SNPs.
Until now, the STR concordance rate has been worse for
amplified than for genomic DNA, even with an input of
200 ng of gDNA into the MDA reaction; whereas optimal
TaqMan®  SNP genotyping is expected for MDA DNA
inputs greater than 4 ng [21]. With less than 5 ng genomic
DNA in the MDA reaction, the amplification bias and the
number of genotyping errors increases [17,22]. Similar
technical limitations were also reported when MDA was
considered for pre-implation genetic diagnosis, with up to
32% ADO for single-cell samples [6].
Recently, we developed and validated an SNP panel for
human identification, rigorously selected to have very
constant frequencies throughout the population tested
and showing high specificity for the human genome [5].
The average size of our amplicons (77 bp) is much less
than current forensic markers, making them more sensi-
tive for LCN DNA and less prone to PCR bias.
Our aim in this work was to assess the applicability of
MDA to forensic SNP genotyping by performing a com-
parative analysis of genomic and MDA DNA samples. A
26-SNPs TaqMan panel specifically designed for LCN
and/or severely degraded genomic DNA was typed on 100
genomic as well as MDA DNA samples. We have con-
firmed the utility of a new TaqMan SNP typing reaction
mix for typing degraded DNA samples. Also, amplifica-
tion of experimentally degraded DNA using MDA, prior to
TaqMan assays, eliminated a 4% failure rate for genotyp-
ing calls that occurred for unamplified genomic DNA
samples. We have optimised the performance of TaqMan
SNP typing of amplified LCN DNA and also tested the
ability of MDA to type ten artificially-degraded DNA sam-
ples, which gave no results when analyzed by current
forensic methods.
Results
The aim of this work was to assess the applicability of
MDA to forensic SNP genotyping. We explored the possi-
bility of generating, from a minimal amount of input
DNA (≤ 1 ng) in the MDA reaction, genome-equivalent
DNA that can be efficiently and accurately typed for a
large number of SNPs. We used a 26-SNPs TaqMan panel
recently developed for LCN and/or severely-degraded
genomic DNA.
We first assessed the performance of multiple displace-
ment amplification (MDA) in terms of genotype concord-
ance between gDNA (50 ng) used as reference genotype,
genomic and amplified LCN DNA (≤ 1 ng). Initially, a
human-specific real-time PCR assay, a Quantifiler™
Human DNA Quantification Kit (Applied Biosystems,
Foster City, CA), was used to quantify the genomic DNA
in 100 selected samples. All the samples were re-
sequenced to assess the genotype at each locus tested. We
then prepared serial dilutions of the DNA to obtain con-
centrations ranging from 1 to 0.01 ng/μl. MDA was per-
formed on 1 μl of the three serial dilutions (1 ng, 0.1 ng,
0.01 ng) for each sample. The MDA products were quan-
tified using the Quantifiler™ Human DNA Quantification
Kit; 14.5, 1.5 and 0.27 μg of DNA were produced from the
1 ng, 0.1 ng and 0.01 ng dilutions, respectively. These
quantities are only indicative, because Quantifiler ampli-
fies a small fraction of the hTERT gene, which is located
adjacent to the 5p telomere, and previous studies have
shown that telomeric regions may be under-represented
[16]. We also quantified the MDA products using Nano-
drop spectrophotometer. The mean final yields of MDA
obtained from the 1 ng, 0.1 ng and 0.01 ng dilutions were
19.5 μg, 8.5 μg and 6.5 μg, respectively. As previously
reported [23] a considerable part of DNA obtained after
MDA was a nonspecific DNA products. The RNAse P real-
time assay was performed to estimate the amount of spe-
cific DNA obtained after MDA (10.0 μg, 2.6 μg and 0.3 μg
for each dilutions respectively). TaqMan assays were per-
formed on 1 μl of MDA DNA and gDNA. To evaluate the
genotype concordance, all the TaqMan assay results from
serial dilutions of gDNA and MDA DNA (1 ng, 0.1 ng and
0.01 ng) were compared to genotypes previously con-
firmed by direct re-sequencing of the same samples (50
ng). In parallel, TaqMan SNP assay results were examined
on the same dilutions of gDNA as technical controls
(Additional file 1). Optimal genotype concordance
(100%) was observed between the sequence and TaqMan.
The TaqMan assay performed on 1 ng of genomic DNABMC Genomics 2009, 10:159 http://www.biomedcentral.com/1471-2164/10/159
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revealed no failure of amplification (100% call rate) and
optimum genotype concordance (Additional file 1). The
TaqMan assay performed on an input of 1 ng in MDA
revealed PCR failure for the marker rs11881170
(99.960% call rate) but perfect genotype concordance.
When the TaqMan assay was performed on 0.1 ng of
genomic DNA, 100% genotype concordance was con-
firmed but there was failure of amplification in two sam-
ples for the markers rs3130315 and rs10866988, in six
samples for marker rs585070 and in four samples for
rs873289, resulting in a call rate of 99.461%. The TaqMan
assay performed on a 0.1 ng input in MDA revealed a sin-
gle PCR failure for the same marker, rs11881170
(99.961% call rate) and a single genotype discrepancy for
rs1981752 (concordance rate 99.961%). When the Taq-
Man assay was performed on 0.01 ng of genomic DNA,
100% genotype concordance was again confirmed but
there were more failures of amplification: in four samples
for marker rs3130315, in two for marker rs585070, in 14
for rs1506981, in four for rs478347 and in six for
rs873289. The resulting average call rate was 98.846%. In
contrast, the TaqMan assay performed on a 0.01 ng input
in MDA revealed a non-absolute concordance rate
(99.379%) with two genotype discrepancies observed for
marker rs2278741, two for rs7740233, two for
rs10866988, two for rs1533800, two for rs154659 and
three for rs873289. It is nevertheless remarkable that
more positive calls were observed with 0.01 ng input of
MDA-DNA than with unamplified DNA at same dilution.
In particular, 20 samples failed to be typed (99.230% call
rate) compared to 30 PCR failures with unamplified DNA
at 0.01 ng dilution.
In order to determine whether a different reaction mixture
might improve both concordance and call rates, we tested
a recently-released master mix, the TaqMan® Genotyping
Master Mix (Applied Biosystems). This is able to optimize
the preferential binding of the allele-specific probe, pro-
viding better separation and clustering of alleles and con-
sistently strong fluorescence signals. Better results were
obtained by repeating the same serial experiments under
identical conditions using this new reaction mix (Addi-
tional file 2). In particular, all three dilutions of genomic
DNA gave 100% results for both concordance and call
rates. Also, we observed 100% concordance and call rates
for MDA inputs of 1 ng and 0.1 ng DNA and 99.923%
concordance and call rates for an MDA input of 0.01 ng
(Additional file 2). We failed to assess the correct geno-
type in two out of 2598 samples, resulting in a genotyping
error rate of 7.7 × 10-4. The two genotype discrepancies
observed in MDA were ADO (false homozygous), and we
also failed to find evidence that the typing results corre-
lated with the GC content and/or the distance to telom-
eres. We note that this rate of genotype discrepancy is
much lower than those reported for current STR forensic
protocols [23,24]. We also never observed positive ampli-
fication in negative controls.
On the basis of these findings we selected the TaqMan®
Genotyping Master Mix as the default reaction mixture for
our panel and for the further experiments presented here.
Artificially degraded samples
A specific digestion was performed to degrade 10 genomic
DNA samples in such a way as to prevent the amplifica-
tion of specific loci by current forensic technology (AMP-
FlSTR®  Identifiler®  kit). Control DNA was randomly
degraded by DNase I (Promega Madison, WI, USA). The
digestion reactions were stopped after 30, 60 and 180 s
and DNase was removed by phenol-chloroform extrac-
tion. The average length of the degraded DNA (ranging
from approximately 80 bp down to less than 50 bp for the
digestion stopped after 180 s) was determined on an aga-
rose gel (Figure 1). The digested DNA (180s) was sub-
jected to MDA and quantified using a Quantifiler™
Human DNA Quantification Kit (Applied Biosystems,
Foster City, CA), revealing an average amount of 2.41 ng.
When we tried to amplify the 180 s-degraded genomic
DNA samples with AMPFlSTR® Identifiler® kit (Applied
Biosystems) under standard conditions [4], we failed to
obtain positive results. The digested DNA (180s) was
typed for the selected SNPs with or without prior MDA.
The results of the TaqMan SNP genotypes obtained from
gDNA and MDA DNA are shown in the Additional file 3.
For degraded DNA samples, more than 4% of genotyping
assays failed without a pre-amplification step using MDA.
All of the samples could be genotyped following the MDA
step.
Discussion
In this work, we wished to investigate whether real-time
TaqMan assays validated for use with low copy number (1
ng, 0.1 ng and 0.01 ng) or severely degraded genomic
DNA might be of value for optimizing the performance of
genotyping of MDA DNA.
To address this issue, we tested two independent proto-
cols using our recently-developed forensic panel of SNPs.
The first protocol revealed dissimilar results when
genomic and MDA DNA were analyzed. In particular, 14
and 30 genomic DNA samples were not amplified with
0.1 ng and 0.01 ng dilutions, respectively, but all geno-
types were concordant with the controls. In contrast, only
one, one and 20 MDA DNA samples failed to be amplified
with the 1 ng, 0.1 ng and 0.01 ng input dilutions, respec-
tively. However, one MDA DNA sample (for inputs of 1
ng and 0.1 ng) revealed a genotype discordant with the
controls, and 36 MDA DNA samples (for input of 0.01 ng)
gave results dissimilar to the sequenced controls.BMC Genomics 2009, 10:159 http://www.biomedcentral.com/1471-2164/10/159
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All discordant genotypes were false homozygous samples
resulting from the complete failure of amplification of
one allele in MDA (allele dropout, ADO) [7]. We there-
fore decided to use a different master mix specifically
designed to optimize the preferential binding of the
allele-specific probe. We repeated the experiments and
obtained better results. We observed 100% concordance
and call rate for all dilutions of genomic DNA and for
inputs of 1 ng and 0.1 ng in MDA. Furthermore, when
inputs of 0.01 ng were analyzed, we observed a single PCR
failure and only two samples gave results dissimilar to the
controls. The resulting concordance and call rate were
therefore increased to 99.923% for a 0.01 ng input in the
MDA reaction, resulting in a probability of genotyping
error of 7.7 × 10-4, quite similar to that reported for STRs.
Such results suggest that in combination with extra-short
TaqMan assays and the specifically-designed master mix,
MDA gave optimal findings in terms of sensitivity, repro-
ducibility and robustness of genotyping. Independent
studies have suggested that replicate MDA reactions
should be pooled prior to genotyping in order to over-
come the frequency of ADO and/or genotyping errors
[25]. Tzvetkov observed that the concordance between
MDA and gDNA genotypes shows a small but significant
improvement (0.5%) in pooled samples compared to sin-
gle MDA. In our opinion, this strategy could be applied
when sufficient DNA template is available.
Nevertheless, the comparison between genomic and
amplified DNA showed that MDA does not improve our
ability to type LCN DNA for single SNPs, as demonstrated
by the better concordance and PCR failure rates in
genomic than in MDA DNA. The genotype concordance
and PCR failure rates were 100% and 99.923% in MDA
DNA and genomic DNA respectively. However, it should
be noted that MDA amplification produces large amounts
of DNA, so it is possible to type many SNPs; in contrast,
genomic DNA is often present in limited quantities so
fewer SNPs can be typed. Finally, MDA allowed us to type
a large number of SNPs starting from LCN DNA as tem-
plate. Moreover, our experiments on artificially-degraded
DNA provide evidence that MDA can enhance our capac-
ity to type severely-degraded samples. In our experiments,
nine samples failed to be amplified in genomic DNA but
were successfully typed in the amplified DNA. We
observed 100% concordance and call rate for all SNPs
using MDA on degraded DNA. The quality of our results
in typing digested DNA by MDA was surprising, although
this has also been reported to a lesser extent for STR typing
[16]. Even though we typed completely-digested DNA
(the average length of the degraded DNA (180s) was 80
bp down to less than 50 bp), it is likely that a small
number of remaining intact fragments of template were
amplified by MDA. In our opinion, these results depend
on the marker types, the amplicon sizes and the genotyp-
ing technique. The results confirm and extend previous
comparative analyses of SNP and STR typing in degraded
forensic DNA (without MDA), demonstrating that good
markers for degraded DNA depend on a small amplicon
size [26]. Here, very small amplicons (77 bp on average)
have been typed by the most sensitive genotyping assay.
Finally, we recommend using MDA in order to overcome
limitations of DNA quantity (when the amount of DNA is
limited) or when only poor-quality DNA samples are
available (severely-degraded samples, to increase the
number of typed loci).
Agarose gel (1.0%) analysis of digested DNA samples Figure 1
Agarose gel (1.0%) analysis of digested DNA samples. 
Lanes M are the size markers (50 bp ladder), lane 1 undi-
gested genomic DNA, lanes 2–4 the digestion stopped after 
30, 60 and 180 s, respectively. We decided to type samples 
digested for 180s, since they did not show evidence of par-
tially-digested DNA fragments.BMC Genomics 2009, 10:159 http://www.biomedcentral.com/1471-2164/10/159
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We would also point out that 0.26 ng of genomic DNA
(0.01 ng for each locus) is needed to type all 21 autosomal
SNPs of our panel and 5 extra SNPs [5,27] successfully. It
is also noteworthy that under these conditions, even
though Real-Time PCR cannot allow multiplexing of the
PCR, the amount of DNA needed to type a panel of SNPs
in singleplex is comparable to current forensic STR meth-
ods and is much less than is needed to type forensic SNPs,
as reported elsewhere [27]. As a result, its use in forensic
practice should be seriously considered when traditional
forensic kits fail.
If the amount of DNA proves insufficient to type all SNPs
independently, it will be possible to apply MDA even in
LCN templates. In this case, only 0.01 ng of input DNA is
needed to type a large number of SNPs (even more than
the 26 reported here). This amount of DNA is much less
than needed in the forensic protocols reported to date, so
it represents a significant improvement in current forensic
DNA protocols. As mentioned above, the possibility of a
technical artefact (i.e. ADO) or a mis-genotyping follow-
ing MDA with 0.01 ng of input DNA is 7.7 × 10-4. This is
a lower error rate than that reported for the STRs used for
forensic typing. Moreover, the mutation rate is higher in
STRs than in SNPs: germline mutations at these STR loci
lead to problems in the interpretation of genetic profile
results.
In order to compare SNP typing between two or more
samples, we can state – by analogy with STR analysis –
that there is a match (biological compatibility) when
there are no differences at genotypic level for any of the
SNPs tested. In contrast, if SNP genotypes show differ-
ences, we can state that the samples considered originated
from different sources (exclusion). Finally, if SNP geno-
types show just a few differences (one or two), we can
state that the data are inconclusive because the informa-
tion is ambiguous or insufficient to support any conclu-
sion, since genotyping errors or ADO events cannot be
excluded. Our results suggest that the probability of two
genotyping errors or ADOs in the same sample is 5.9 × 10-
7 when only 10 pg of DNA are analyzed. Although this
probability is quite low, homozygous genotypes in LCN
DNA should be used with caution to exclude a match
(compatibility): in this case, additional heterozygous
markers should also be considered.
Conclusion
In conclusion these results provide evidence that MDA
can be considered suitable for SNP-based forensic proto-
cols and in general when samples fail to give interpretable
STR results. The demonstrated potential of MDA, in con-
trast to all previous WGA methods, is particularly promis-
ing and might have broad applications and significant
implications in the areas of forensics and genetic studies.
Methods
gDNA samples
Blood or saliva samples from 100 unrelated subjects were
extracted using QIAamp DNA Blood Mini Kit (Qiagen
Inc., Valencia, CA). All samples were quantified using a
Quantifiler™ Human DNA Quantification Kit (Applied
Biosystems) according with manufacturer's protocols
[28]. The hundred samples were diluted to 1, 0.1 and 0.01
ng/μl with double-distilled water.
Amplification and sequencing
PCR amplifications were carried out separately for each
SNP using 1 μl of DNA in a 30 μl reaction volume contain-
ing final concentrations of 1× True Allele Master Mix
(Applied Biosystems) and 0.2 μM of each primer (Invitro-
gen) plus water. Oligonucleotide sequences have been
described elsewhere [5,28]. The amplicons were dena-
tured at 95°C (12 min), put through 28 reaction cycles of
95°C for 30 s, 58–65°C for 40 s and 72°C for 40 s, puri-
fied enzymatically (1 U exonuclease I and 2 U alkaline
phosphate) (Ambion, Austin, Texas, USA) and directly
sequenced by cycle sequencing with a BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) using the
same primers as for amplification. The sequencing reac-
tions were carried out in a 20 μl final volume containing
2 μl BigDye Terminator RR Mix, 1 μl 5× Big Dye Sequenc-
ing Buffer, 10 pmol primer, 2–4 μl PCR product and
water. After a first denaturation step at 96°C for 1 min, 28
cycles of 10 s at 96°C, 5 s at 50°C and 2 min at 60°C were
performed. Each template was sequenced in both forward
and reverse directions using the amplification primers.
Sequencing reaction products were purified from the
residual dye terminators using CentriSep columns (Princ-
eton Separations, Adelphia, NY, USA). Electrophoretic
separation was carried out on an ABI Prism 310 Genetic
Analyzer.
DNA degradation
Ten artificially-degraded DNA samples were prepared by
DNAase I digestion (Ambion Inc, Austin, Texas, USA). A
total of 1 μg of DNA was digested with 1 U of DNAase I at
37°C in a solution containing water to 60 μl final volume.
The reactions were stopped after 30, 60 and 180 s, adding
20 μl of the solution at each time point to 2 μl of 20 mM
ethylenediaminetetracetic acid (EDTA). DNase was
removed by phenol-chloroform extraction. To evaluate
the degradation of genomic DNA, 3 μl of the digestion
products were separated on a 1% agarose gel (figure 1).
Whole genome amplification
Multiple displacement amplification WGA (MDA) reac-
tions were performed using a Φ29 DNA polymerase-based
Repli-g Mini kit (Qiagen) for each LCN sample (1, 0.1 and
0.01 ng/μl) and for the degraded samples (180 s digestion
time). A total of 1 μl of genomic DNA was incubated withBMC Genomics 2009, 10:159 http://www.biomedcentral.com/1471-2164/10/159
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D1 solution (containing Reconstituted Buffer DLB and
nuclease-free water) and then with N1 solution (contain-
ing Stop Solutions and nuclease-free water) for 3 min and
the products were added to 7.25 μl Repli-g Mini Reaction
Buffer and 0.25 μl Φ29 DNA polymerase. The mixture was
incubated at 30°C for 8 h followed by heat-inactivation at
65°C for 3 min.
WGA products were quantified using three different meth-
ods: the Quantifiler™ Human DNA Quantification Kit
(Applied Biosystems), Real-Time RNase P gene dosage
assay (Applied Biosystems), and Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE, USA) at 260 nm. Quantitative Real-Time PCR
reactions for RNase P gene was carry out in a final volume
of 25 μl containing 12.5 μl of 1× TaqMan® Expression PCR
Master Mix (Applied Biosystems), 1.25 μl TaqMan® RNase
P Control Reagents (Applied Biosystems) and water. For
the absolute quantification, calibration curve was gener-
ate with a serial diluitions of gDNA sample of known con-
centration ranging from 0.01 to 100 ng/μl.
SNP genotyping of LCN
Serial dilutions of gDNA (1 ng, 0.1 ng and 0.01 ng) and 1
μl of each of the three MDA reactions (starting from DNA
inputs of 1 ng, 0.1 ng and 0.01 ng) were used as templates
for genotyping the 26 SNPs using the TaqMan® Assay, to
evaluate the allele calling and concordance rates. The list
of SNPs together with their relative chromosome loca-
tions, PCR primer sequences and relative TaqMan® probes
were as described [5,28]. The reaction mixture for all SNP
assays was as follows: 6.25 μl 1× TaqMan® Universal Mas-
ter Mix, 0.25 μl TaqMan Genotyping Assay and water to a
final volume of 12.5 μl. Cycle conditions were 50°C for 2
min, 95°C for 10 min, 50 cycles of 95°C for 30 s and
60°C for 1 min, performed in a 96-well optical plate. Each
plate contained three positive controls (samples previ-
ously confirmed by direct sequencing as heterozygous and
both homozygous types) and two negative controls.
gDNA and all MDA DNA were amplified simultaneously
in duplicate, and genotypes were determined.
For the MDA DNA reaction, the new TaqMan® Genotyping
Master Mix was used. The reaction mixture was: 12.5 μl 1×
TaqMan® Genotyping Master Mix, 0.25 μl TaqMan® Geno-
typing Assay and water to a final volume of 25 μl.
Fluorescence was detected using an ABI 7500 Sequence
Detection System and genotypes were manually scored
using Sequence Detection Software 2.0 (Applied Biosys-
tems).
The SNP genotype call rate was calculated by dividing the
number of correct amplification genotypes by the number
of attempted genotypes; the SNP genotype concordance
rate was calculated by dividing the number of concordant
genotypes by the number of completed genotypes. The
MDA DNA concordance rate was defined as the number
of instances in which an MDA DNA SNP genotype dif-
fered from the scored gDNA SNP genotype.
SNP genotyping assay of degraded samples
Aliquots of 1 μl of the 10 artificially-degraded DNA sam-
ples (180 s degradation time with DNAase I) and 1 μl of
the same samples after the MDA reaction, together with 1
μl of genomic DNA, were tested for genotyping of the 26
SNPs on ABI 7500 using: 12.5 μl 1× TaqMan® Genotyping
Master Mix, 0.25 μl TaqMan® Genotyping Assay, and water
to a final volume of 25 μl. Artificially-degraded DNA, arti-
ficially-degraded MDA DNA and genomic DNA were
amplified simultaneously in duplicate for each SNP ana-
lyzed.
STR analysis
Artificially-degraded DNA (180 s degradation time with
DNAase I) was used as template for the AmpFlSTR® Iden-
tifiler® Assay (Applied Biosystems). The AmpFlSTR® Iden-
tifiler® PCR Amplification Kit was used to amplify 15 STR
loci simultaneously: D16S539, D2S1338, D19S433,
D13S317, D8S1179, vWA, D21S11, D7S820, CSF1PO,
D3S1358, THO1, D18S51, D5S818, FGA, TPOX and
AMEL for gender determination. Amplification was car-
ried out as previously described [4]. The total volume of
each reaction was 25 μl. The PCR amplification was car-
ried out in a 9700 Gene Amp PCR System Thermal Cycler
(Applied Biosystems) according to the manufacturer's rec-
ommendations. Electrophoresis of the amplification
products was performed on an ABI PRISM 310 Genetic
Analyzer. The raw data were compiled and analyzed using
accessory software GeneMapper™ 3.2 (Applied Biosys-
tems).
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